It was on Schwab news from Thomson Reuters but can't find it. It was orphan drug status for galaxolone for Fragile X syndrome. Can't find it on Thomson Reuters though. So delete the post. No big deal.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.